Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- market value
- Rules
- 5550(b)(2)
Exact text from the filing
November 7, 2024, the Company received a separate letter from Nasdaq indicating that the Company’s market value of its listed securities has been below the minimum $35,000,000 required for continued listing on the Nasdaq Capital Market, as set forth in Listing Rule 5550(b)(2) for the previous thirty consecutive trading days. In accordance with the terms of the previously imposed “Mandatory Panel Monitor” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), the Nasdaq Listing Qualifications Staff (the “Staff”) did not grant the Company a grace period but rather issued a delist determin
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
December 12, 2024, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on November 7, 2024, the Company received a separate letter from Nasdaq indicating that the Company’s market value of its listed securities has been below the minimum $35,000,000 required for continued listing on the Nasdaq Cap
View on SEC.gov